PMA device
Enlite Sensor
Medtronic, Inc. · Automated Insulin Dosing , Threshold Suspend (OZO, Class III) · First FDA decision Nov 12, 2015, newest Nov 12, 2015Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
30
Naming "Enlite"
MAUDE reports
25,717
Brand "Enlite", since 2015
PubMed studies
67
Mentioning "Enlite"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Enlite Sensor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ENLITE SENSORPMA supplement
P120010-S029 · Decided Nov 12, 2015 · 489 days after receipt · Normal 180 Day Track
Device type: Automated insulin dosing , threshold suspend (OZO) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Enlite", any status and sponsor, newest update first.
- Closed Loop From Onset in Type 1 DiabetesStatus unknown
University of CambridgeAcademic, hospital or other
NCT02871089 · 96 participants (planned) · Start Jan 2017 · Primary completion Jul 31, 2023
Device: Closed-loop system (Florence M or CamAPS FX) · For: Diabetes Mellitus; Type 1 Diabetes
Sites: Southampton, United Kingdom; Nottingham, United Kingdom; Oxford, United Kingdom · 7 sites in all
29 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Enlite", and for the whole product code for context.
This brand
25,717 reports: 22,333 malfunction, 3,345 injury, 32 death
Whole product code OZO
424,597 reports: 337,031 malfunction, 86,136 injury, 1,411 death
Newest reports for this brand
- SENSOR ENLITE MMT-7008AInjury
MEDTRONIC PUERTO RICO OPERATIONS CO.
2032227-2026-180340 · Received May 26, 2026 · Event dated Jul 9, 2018
Device type: Automated Insulin Dosing , Threshold Suspend (OZO)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fatigue; Hyperglycemia; Nausea; Elevated Ketones/ Diabetic Ketoacidosis
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MiniMed 530G Insulin Pump (MMT-551, MMT-751)Open, Classified
Z-1751-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Automated Insulin Dosing , Threshold Suspend (OZO)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Enlite"[tiab]. The summary above synthesizes these.
- ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
Videnovic A, Coffey CS, Klerman EB, et al. · Mov Disord · 2025Randomized Controlled Trial, Clinical Trial, Phase II
- Experience with the Enlite sensor in a multicenter pediatric study.
Evans K, Richardson C, Landry A, et al. · Diabetes Educ · 2015Multicenter Study, Randomized Controlled Trial
- The Accuracy of Continuous Glucose Monitoring in the Medical Intensive Care Unit.
Tingsarat W, Buranasupkajorn P, Khovidhunkit W, et al. · J Diabetes Sci Technol · 2022Research Support, Non-U.S. Gov't
- TREC/KREC Newborn Screening followed by Next-Generation Sequencing for Severe Combined Immunodeficiency in Japan.
Wakamatsu M, Kojima D, Muramatsu H, et al. · J Clin Immunol · 2022Research Support, Non-U.S. Gov't
- A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite.
Damiano ER, McKeon K, El-Khatib FH, et al. · J Diabetes Sci Technol · 2014Comparative Study, Evaluation Study
- Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.
Bailey TS, Ahmann A, Brazg R, et al. · Diabetes Technol Ther · 2014Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of Isobornyl Acrylate Content in Medical Devices for Diabetes Treatment.
Kamann S, Oppel E, Liu F, et al. · Diabetes Technol Ther · 2019
- Newborn Screening for SCID. Experience in Spain (Catalonia).
Argudo-Ramírez A, Martín-Nalda A, González de Aledo-Castillo JM, et al. · Int J Neonatal Screen · 2021
- Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation.
Forlenza GP, Nathan BM, Moran A, et al. · Diabetes Technol Ther · 2016Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients.
Hyry HSI, Liippo JP, Virtanen HM · Contact Dermatitis · 2019
- A Comparison of Time Delay in Three Continuous Glucose Monitors for Adolescents and Adults.
Sinha M, McKeon KM, Parker S, et al. · J Diabetes Sci Technol · 2017Comparative Study
- Accuracy of Continuous Glucose Monitoring Measurements in Normo-Glycemic Individuals.
Akintola AA, Noordam R, Jansen SW, et al. · PLoS One · 2015Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code OZO.
- Minimed 530G SystemMedtronic, Inc. · PMA 2017
- MiniMed 630G Insulin Pump, Guardian Link (3) TransmitterMedtronic Minimed · PMA 2018
- t:slim X2 Insulin Pump with Basal-IQ TechnologyTandem Diabetes Care, Inc. · PMA 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.